Literature DB >> 10078741

Cerebellar ataxia with glutamic acid decarboxylase autoantibodies.

M Abele1, M Weller, S Mescheriakov, K Bürk, J Dichgans, T Klockgether.   

Abstract

Degenerative cerebellar ataxia with autoantibodies against glutamic acid decarboxylase (GAD) is a rare disorder and may represent a subset of ataxias previously classified as idiopathic. The authors report a patient with progressive cerebellar ataxia, insulin-dependent diabetes mellitus, and GAD antibodies who responded to i.v. immunoglobulins.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10078741     DOI： 10.1212/wnl.52.4.857

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  17 in total

1.  Cerebellar degeneration and polyglandular autoimmune syndrome with anti-glutamic acid decarboxylase antibodies.

Authors:  S Rüegg; M Stahl; M Bühlmann; A Dupont; P A Lyrer; R L Humbel; A J Steck
Journal:  J Neurol       Date:  2002-03       Impact factor: 4.849

Review 2.  Autoimmune stiff person syndrome and related myelopathies: understanding of electrophysiological and immunological processes.

Authors:  Goran Rakocevic; Mary Kay Floeter
Journal:  Muscle Nerve       Date:  2012-05       Impact factor: 3.217

3.  Low-Titre GAD Antibody-Associated Late-Onset Cerebellar Ataxia with a Significant Clinical Response to Intravenous Immunoglobulin Treatment.

Authors:  Timotej Petrijan; Marija Menih
Journal:  Cerebellum       Date:  2017-08       Impact factor: 3.847

Review 4.  Cerebellar disease associated with anti-glutamic acid decarboxylase antibodies: review.

Authors:  José Fidel Baizabal-Carvallo; Marlene Alonso-Juarez
Journal:  J Neural Transm (Vienna)       Date:  2017-07-08       Impact factor: 3.575

5.  Intravenous immunoglobulin and rituximab for cerebellar ataxia with glutamic acid decarboxylase autoantibodies.

Authors:  Vincent Planche; Ana Marques; Miguel Ulla; Marc Ruivard; Franck Durif
Journal:  Cerebellum       Date:  2014-06       Impact factor: 3.847

6.  GABA-A receptor impairment in cerebellar ataxia with anti-glutamic acid decarboxylase antibodies.

Authors:  Yasushi Hosoi; Makiko Suzuki-Sakao; Tatsuhiro Terada; Takashi Konishi; Yasuomi Ouchi; Hiroaki Miyajima; Satoshi Kono
Journal:  J Neurol       Date:  2013-10-05       Impact factor: 4.849

7.  Cerebellar ataxia and glutamic acid decarboxylase antibodies: immunologic profile and long-term effect of immunotherapy.

Authors:  Helena Ariño; Nuria Gresa-Arribas; Yolanda Blanco; Eugenia Martínez-Hernández; Lidia Sabater; Mar Petit-Pedrol; Idoia Rouco; Luis Bataller; Josep O Dalmau; Albert Saiz; Francesc Graus
Journal:  JAMA Neurol       Date:  2014-08       Impact factor: 18.302

8.  Cerebellar ataxia associated with anti-glutamic acid decarboxylase autoantibodies.

Authors:  M Vianello; B Tavolato; M Armani; B Giometto
Journal:  Cerebellum       Date:  2003       Impact factor: 3.847

9.  Sporadic ataxias in Japan--a population-based epidemiological study.

Authors:  Shoji Tsuji; Osamu Onodera; Jun Goto; Masatoyo Nishizawa
Journal:  Cerebellum       Date:  2008       Impact factor: 3.847

10.  T-cell reactivity to glutamic acid decarboxylase in stiff-man syndrome and cerebellar ataxia associated with polyendocrine autoimmunity.

Authors:  M Costa; A Saiz; R Casamitjana; M Fernández Castañer; A Sanmartí; F Graus; D Jaraquemada
Journal:  Clin Exp Immunol       Date:  2002-09       Impact factor: 4.330
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.